Medtronic's (MDT +0.2%) CoreValve heart implant increased 1-year survival rates amongst patients...
Monday, October 22, 2012, 9:48 AM ETMedtronic's (MDT +0.2%) CoreValve heart implant increased 1-year survival rates amongst patients in a study and it improved their quality of life. Separately, a trial of the company's Symplicity renal denervation treatment helped reduce blood pressure in patients with "treatment-resistant hypertension," who have a high risk of "various cardiovascular events."
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles